Clinical Trial

An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity

Name: An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity — clinical trial record (NCT07555639)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GERSOM

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

National multicenter prospective study, involving the enrollment of approximately 1,500 patients with ovarian cancer, 1,500 patients with breast cancer, and 1,000 patients with colorectal cancer.

Trial Details

NCT Number	NCT07555639
Lead Sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions	Colon Cancer, Breast Cancer, Ovarian Cancer, Genetic Risk Factors
Enrollment	4,000 participants
Start Date	2019-11-21
Primary Completion	2022-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-29